Live Quote · NASDAQCYTOHealthcare· Biotechnology

Altamira Therapeutics Ltd.

$0.30 100.00%(+$0.30)
TickerSpark Score
49/100
Weak
100
Valuation
20
Profitability
20
Growth
56
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTO research report →

52-Week Range0% of range
Low
$0.30
Current
$0.30
High
$0.42
Company Overviewaltamiratherapeutics.com

About the company

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens.

CEO
Thomas Meyer
IPO
2014
Employees
10
HQ
Hamilton, BM

Price Chart

-82.25% · this period
$2.42$1.24$0.05Mar 18Sep 17Feb 10
Valuation
Market Cap
$1.13M
P/E
-0.02
P/S
0.00
P/B
0.02
EV/EBITDA
-0.09
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-111.64%
ROIC
-77.74%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-7,270,000 · 0.00%
EPS
$-14.81 · 0.00%
Op Income
$-5,916,000
FCF YoY
45.99%
Performance & Tape
52W High
$0.42
52W Low
$0.30
50D MA
$0.17
200D MA
$0.60
Beta
2.44
Avg Volume
244.03K

Get TickerSpark's AI analysis on CYTO

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 8, 08CARTER STEPHENsell10,000
May 8, 08LOKAY KEVIN Gsell100,000
May 8, 08LOKAY KEVIN Gsell185,439
May 8, 08MOLLICA JOSEPH Asell10,000
Nov 13, 07LOKAY KEVIN Gother500,000
Nov 13, 07LOKAY KEVIN Gother350,877
Nov 13, 07LOKAY KEVIN Gother175,439
Jun 14, 07LOKAY KEVIN Gother10,000
Jun 13, 07LOKAY KEVIN Gother10,000
Jun 14, 07MOLLICA JOSEPH Aother10,000
Coverage · CYTO

Our CYTO coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CYTO yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CYTO report →
Internal Compare

Similar companies

Peers in the same neighborhood.